MeOmics Technology: Funding, Team & Investors

MeOmics Technology is a company dedicated to advancing personalized medical care, with a specific emphasis on mental health. As a university spin-out, the organization leverages academic research to develop its approach to precision medicine. Its work involves the application of pharmacogenomics, a field that examines how genes affect a person's response to drugs, to improve psychiatric treatments.

Date	Round	Lead Investors	Other Investors	Status
Feb 9, 2026	$408K Undisclosed	Development Bank OF Wales, Women Angels OF Wales	—	Announced

The company operates within the pharmaceutical manufacturing industry, indicating its involvement in the development or production of medical solutions. This focus positions MeOmics Technology at the intersection of biotechnology and mental healthcare, aiming to tailor treatments to individual patient profiles.

Leadership at MeOmics Technology includes Alasdair Pettigrew, who holds the roles of Executive Chair and Acting CEO. His involvement underscores the company's commitment to strategic development and operational execution in its specialized field. Additionally, J.T.R.W. is noted as a shareholder in the company, further indicating key individual involvement.

MeOmics Technology is headquartered in Cardiff, United Kingdom. Its foundational structure as a university spin-out suggests a strong link to research and development, aiming to translate scientific discoveries into practical applications for patient care in mental health.

What specific area of personalized medicine does MeOmics Technology focus on?

MeOmics Technology focuses on personalized medical care within the mental health sector, specifically utilizing pharmacogenomics for precision medicine in psychiatry.

Who are some key individuals associated with MeOmics Technology?

Alasdair Pettigrew serves as Executive Chair and Acting CEO, while J.T.R.W. is a shareholder in MeOmics Technology Ltd.